E. coli BL21 (DE3) (Novagen, USA) was used as the host for gene expression. The pET32a(+) expression plasmid was obtained from Novagen, USA. Restriction enzymes and modifying enzymes were purchased from Takara, Japan and enterokinase was obtained from Invitrogen, USA.

The gene encoding the first 34 amino acids of PTH, 5 amino acid residues (Asp-Asp-Asp-Asp-Lys), thioredoxin and His₆ tag sequence, were synthesized by CinnaGen, Iran. PTH(1-34) gene was located at the C terminal of Lys. This sequence was ligated into pET32a+ (Invitrogen Co, USA) between Bg1 II -Kpn I site of plasmid, then the pET32a-PTH was transformed into E. coli BL21 as cited in the instruction manual of the kit (Invitrogen Co, USA) (Figure 1). The orientation of the gene was confirmed by restriction enzyme digestion and DNA sequencing (SinaClone, Iran) (data not shown).

A single colony of the fresh E. coli BL21 transformants bearing pET32a-PTH was cultured in 10 ml LB media containing Ampicilin (100 µg/ml) overnight ⁽¹⁷⁾. The cell suspension, 1 ml, was transferred to 300 ml of the same media for an additional 18 hr at 37°C and 160 rpm. The harvested cell suspension was diluted 10-fold in fermentation process with LB Broth containing Ampicilin (100 µg/ml) and cultured in 5L fermentor at 37°C with aeration rate of 1 (v/v/m) and agitation rate of 200-600 rpm. The expression of the His₆-Thioredoxin-hPTH (1-34) fusion protein was induced at OD 0.9 by addition of IPTG (CinnaGen Co., Iran) to a final concentration of 1 mM. The biomass was harvested after 5 hr of fermentation followed by centrifugation at 9500 rpm for 10 min. The cell pellet was kept frozen at -70°C. Polyacrylamidegel electrophoresis in the presence of SDS (SDS-PAGE) was used to determine the expression level of the His₆-thioredoxin-hPTH (1-34) fusion protein.

The frozen biomass of E. coli was resuspended in lysis buffer (20 mM Tris-HCl pH=8 containing 6 M Urea) on ice. The suspended cells were disrupted and homogenized at 1200 Psi, followed by centrifuging at 9500 rpm, 4°C for 45 min. The supernatant containing the fusion protein was collected and applied to Ni-NTA resin (column XK 50/40, GE, USA). The column was equilibrated with 50 mM Tris-HCl pH=8 containing 6 M Urea followed by washing with wash buffer (20 mM Tris-HCl pH=8 containing 6 M Urea, 2 M NaCl). The fusion protein was eluted with elution buffer (20 mM Tris-HCl pH=8 containing 6 M Urea, 2 M NaCl and 18 mM Immidazole). Fractions containing His₆-Thioredoxin-hPTH (1-34) fusion protein were pooled and desalted by dialyzing for 24 hr at 4°C in dialysis buffer (20 mM Tris-HCl pH=8 containing 10% w/w Tween 20,0.1 M CaCl₂).

In order to cleave hPTH from its tag, the desalted fusion protein was digested with enterokinase enzyme (EK MAX, Invitrogen Co., USA) for 16 hr at room temperature with different enzyme units. The digestion reaction was terminated by reducing the pH with 2 M acetic acid.

The digested mixture was applied to size exclusion chromatography column (GE, USA) by FPLC (AKTA purifier, GE, USA) that was equilibrated with 20 mM sodium acetate and 50 mM NaCl Fractions were analyzed by SDS-PAGE. Then hPTH without His₆-thioredoxin tag was pooled and loaded on ion exchange chromatography column with SP sepharose resin (GE, USA). The column was equilibrated and washed with equilibration buffer (0.01 M ammonium acetate pH=4.5 containing 50 mM NaCl) and washing buffer (0.02 M ammonium acetate pH=5.2 containing 0.1 M NaCl), respectively. The recombinant hPTH (1-34) peptide was eluted with 0.02 M Ammonium Acetate and 1 M NaCl. The fractions were collected and kept at 4°C.

To estimate the purity of the SP fractions, RP-HPLC analysis (C18, Agilant, USA) was performed. HPLC chromatogram of hPTH (1-34) was performed using a linear gradient of 100% A, 0% B solutions in 25 min, flow rate 1 ml/min. Solution A contained acetonitril and 0.2 M Na₂SO₄ (1:9 w/w) and solution B contained acetonitril and 0.2 M Na₂SO₄ (1:1 w/w). Sample, rhPTH (1-34), and standard hPTH (Forteo) (Eli Lilly, France) were diluted with dilution buffer (acetonitril and 0.3 M Na₂SO₄, 31/69 w/w) to the final concentration of 0.1 mg/ml. Then 25 µl of each diluted samples were applied to HPLC column. Proteins were monitored by UV detection at 214 nm.

Mass spectrometry was performed to obtain the molecular weight of the protein on a Finnigan LCQ-Classic MALDITOF mass spectrometer.

Preparing sample dilution: Samples containing Forteo (Eli Lilly, France) and rhPTH were diluted to final concentration of 1 µM/ml with DMEM-F12, 1% BSA (Bovine Serum Albumin) (Sigma, USA). Then, a series of dilutions, 1:1000-1:8000 final concentration in the assay, were prepared with DMEM with BSA 1%.

The 30 µM cAMP calibrator (Sigma, USA) was diluted with cAMP Assay Buffer (Catch Point Cyclic-AMP Fluorescent Assay Kit, Molecular Devices, USA) to prepare stock calibrators of 1:1000-1:8000 final concentration in the assay.

Flasks containing UMR 106 cells (ATCC, USA) were treated with 1 ml trypsin (GIBCO, USA) and resuspended to final concentration of 0.1×10⁶ cell/well with DMEM-F12 (GIBCO, USA), 10% FBS (GIBCO, USA). Then 200 µL of cell solution, 20000 cell/well, were transferred to each well of 96 well-plate and incubated for 24 hr. Wells were washed two times with HBSS buffer (Hank's Balanced Salt Solution). Afterwards, 100 µl of each hPTH (1-34) and Forteo, reference standard, (Eli Lilly, France) dilutions were separately added to each well and incubated with gentle shaking at 25°C for 20 min. Samples were discarded and wells were washed twice with 300 µl HBSS. Assay Lysis Solution, 100 µl (Catch Point Cyclic-AMP Fluorescent Assay Kit, Molecular Devices, USA) were added to each well and plate was incubated for 30 min at 37°C.

Cell lysate was mixed gently with multichannel pipette and 40 µl of the solution was transferred to cAMP screen assay plate. Reconstituted Rabbit anti-cAMP antibody, 40 µl, was added to each well except control wells. The plate was placed on shaker for 5 min. Then 40 µl of reconstituted HRP-cAMP conjugate was added to all wells and incubated for 2 hr at room temperature. The plate content was aspirated and washed 4 times with 300 µl wash buffer (Catch Point Cyclic-AMP Fluorescent Assay Kit, Molecular Devices, USA) for each wash. Then 100 µl of Spotlight Red substrate (Catch Point Cyclic-AMP Fluorescent Assay Kit, Molecular Devices, USA) were added to each well. The plate was covered to be protected from light and was incubated in room temperature for 10 min. Fluorescent intensity of the plate was read in Excitation filter 525-530 nm, Emission filter 590-570 nm. The average intensity values (y-axis) were plotted against calibrator concentration (x-axis) to create a calibration or standard curve. To calculate cAMP doses, hPTH samples were interpolated using this curve.

As shown in Figure 1, the gene sequence encoded for amino acids 1-34 from PTH was inserted in the C terminal portion of thioredoxin gene. The DNA sequence for 5 amino acids (Asp-Asp-Asp-Asp-Lys) as a specific recognition site was inserted between PTH gene sequence and the fusion partner DNA sequences. His-tag was added to the downstream of Bgl II site. Two restriction enzyme recognition sequences, BglII and Kpn I, were added to the N terminal and C terminal of the fusion protein, respectively. The construct was inserted into pET32a(+) resulting in pET32a(+)-hPTH34 plasmid.

The expression vector subsequently was transformed into E. coli BL21 (DE3) to form the engineered bacterium. The highest level of expression was obtained 5 hr after induction with IPTG. This level of expression usually makes the recombinant protein hard to solubilise and form inclusion bodies. His₆-Trx fusion partner has beneficial features of high solubility and it provides the possibility of using affinity chromatography for purification. As shown in Figure 2 (lane 1), there is low expression in pre-induction sample. However, the productivity was higher three hours after the induction and reached to the highest level after 5 hr (Figure 2, lane 7).

The fusion protein was purified using Ni-NTA due to the presence of His₆ tag. Then, the fusion partner with 18 kDa, was separated from rhPTH through digestion with enterokinase (Figure 3). The enzyme to substrate ratio was optimized at lowest level, 0.341 per/mg of protein. Two bands, fusion partner 18 kDa and rhPTH 4 kDa, are clearly demonstrated in the SDS-PAGE. Lane 1 is the undigested fusion protein. Lane 2 is rhPTH standard. Lane 3 shows complete digestion fusion protein. Presence of specific digestion site (Asp-Asp-Asp-Asp-Lys) for enterokinase prevents non-specific digestion of rhPTH.

The digested proteins were applied to size exclusion column (Superdex 75) followed by SP sepharose column. The purified rhPTH with more than 97% purity was obtained (Figure 4A: lanes 2, 3, 4, 5, 6, 7 and 8 different fractions from ion exchange column). These findings are in line with what other researchers have previously found ⁽¹²⁾. In our system the purification steps were restricted to three columns. The majority of the impurities were taken during Ni-NTA followed by specific binding to Sp sepharose fast flow column. The final recovery found to be 42% (data not shown) with 99.7% purity. The first 8 N-terminal amino acids of the purified proteins were similar to what was found in standard rhPTH from NIBSC through mass spectroscopy (data not shown).

The purity of rhPTH was confirmed using RP analysis by analytical HPLC (Figure 5). A single sharp peak was demonstrated at retention time of around 20 min. The RP HPLC diagram was the same as the standard sample from NIBSC (data not shown) and the impurities were less than 0.3%. In addition, Mass spectrophotometry analysis show that the molecular weight of rhPTH was 4117.5 Da (Figure 6). The molecular weight of pro-pro-pro PTH was reported as 4311.46 ⁽¹⁴⁾. If Pro-Pro-Pro is eliminated, the right molecular weight (4117.5 Da) will be observed.

The binding of the rhPTH receptors was measured by assaying stimulated cAMP generation by the osteogenic sarcoma cell culture. PTH bioassays in vitro have the most commonly utilized cultured animal tissue, and the tissue extract contains adenlate cyclase and animal cells ⁽¹⁸⁾. PTH binds to its receptors causing a complex response in tissues, cells or extracts that can be measured by the stimulated generation of cAMP ^{(19, 20)}. In the present study, UMR 106 cells were chosen for in vitro determination of rhPTH biological activity.

The purified rPTH increased the cAMP level in UMR 106 cells which is rat osteogenic sarcoma cell line by interaction with surface receptors (Table 1). The positive control was the commercially available rPTH, Forteo. The potency of the sample was 99.7% according to the standards and the testing criteria for protein activity. As it is shown in Table 1, the optical density obtained in each dilution was comparable with what was obtained by Forteo. The standard curve demonstrates validation of the test. The potency of rhPTH was similar to Forteo.